Skip to main content

Showing 11 - 20 of 104 results

Spotlight

July 27, 2023

The Past, Present, and Future of Deprescribing

AMDA’s Drive to Deprescribe (D2D) initiative put practitioners behind the wheel on medication optimization. During a recent AMDA On-The-Go podcast, guest host Jennifer Pruskowski, PharmD, MS, BCPS, BCGP, CPE, sat down with Michael Steinman, MD, co-director of the U.S. Deprescribing Research Network, to tal...
JAMDA

June 17, 2023

Post Hoc Analyses of a Randomized Controlled Trial for the Effect of Pharmacist Deprescribing Intervention on the Anticholinergic Burden in Frail Community-Dwelling Older Adults

Anticholinergic burden is detrimental to cognitive health. Multiple studies found that a high anticholinergic burden is associated with an increased risk for dementia, changes to the brain structure, function, and cognitive decline. We performed a post hoc analysis of a randomized controlled deprescribing ...